用于治疗中度至重度慢性斑块性牛皮的生物类药物
Paolo Gisondi1, Francesco Bellinato1, Tea Curic1
1Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
Psoriasis (Auckland, N.Z.)
|August 27, 2025
概括
生物类似药物为治疗中度至重度牛皮提供了昂贵的生物药物的经济有效替代品. 这些非常相似的生物产品确保了可比的安全性和有效性,改善了患者的获取和降低了医疗保健成本.
科学领域:
- 皮肤病学
- 免疫学
- 药物经济学
背景情况:
- 牛皮是一种慢性炎症性皮肤疾病,
- 系统治疗适用于影响身体关键部位的中度至重度牛皮.
- 生物和小分子疗法改善了生活质量,
研究的目的:
- 审查用于治疗牛皮的生物类似药物.
- 突出生物类似药的潜在节省成本的好处.
- 讨论特定的生物制剂及其生物类似物.
主要方法:
- 对现有文献进行叙述性回顾.
- 专注于已批准的牛皮生物疗法.
- 对生物类似概念和成本影响的分析.
主要成果:
- 生物仿制药在安全性,纯度和有效性方面与参考生物药物非常相似.
- 生物仿制药可以降低医疗费用.
- 可以获得更先进的牛皮治疗方法.
结论:
- 生物仿制药为改善获得有效牛皮治疗的机会提供了重要机会.
- 采用生物仿制药可以减轻医疗保健系统的财务负担.
- 需要进一步讨论特定的生物类似药物,如阿达利木马布,因弗利克西马布,伊坦塞普和乌斯特基努马布.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
252
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
252
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189


